If you are looking to bolster your portfolio with some ASX 200 shares, you may want to look at the two listed below.
Here's why these ASX 200 shares are highly rated right now:
Image source: Getty Images
CSL Limited (ASX: CSL)
The first ASX 200 share to look at is CSL. It is one of the world's leading biotherapeutics companies, comprising the CSL Behring and Seqirus businesses. CSL Behring is the global leader in plasma therapies and Seqirus is the second largest influenza vaccines business.
It recently released its full year results and revealed a 9.6% increase in constant currency revenue to US$10,026 million and a 10% lift in profit after tax to US$2,307 million. The latter was ahead of its guidance of 3% to 8% growth.
And while plasma collection headwinds are expected to weigh on its performance in FY 2022 and lead to a decline in profit, its long term prospects remain very positive. This is thanks to strong demand for its key therapies and its pipeline of potentially lucrative products under development.
Morgans is positive on the company. The broker currently has an add rating and $324.40 price target on its shares.
REA Group Limited (ASX: REA)
Another ASX 200 share for investors to look at is REA Group. It is the leading player in real estate listings in the Australian market with its realestate.com.au website.
In addition to this, the company has a number of complementary businesses both at home and internationally. It has also just strengthened its offering with the acquisition of Mortgage Choice and an interest in Simpology.
All in all, this appears to have left REA Group in a strong position to continue its solid growth over the next decade.
Goldman Sachs certainly expects this to be the case. It is very bullish on REA Group's prospects and has a buy rating and $190.00 price target on its shares.
